Kornimate/medical-research-clean huggingface dataset:
impact of multi-component intervention on suspected asthma population

Conditions: Multimorbidity; Chronic Asthma; Population Medicine

Summary: study participants: suspected asthma population, defined as individuals whose score of asthma screening questionnaire used in ecrhs study exceeds 0 and whose age is 35 and above. intervention: within the intervention arm, we have constructed a population-based pay-for-performance mechanism to encourage medical practitioners to care for population health. for study participants in the intervention arm, we will ask them to finish an online ecrhs questionnaire with notification of his or her suspected asthma status. individuals whose score of ecrhs asthma screening exceeds 0 will be given a face-to-face survey, simple physical examination, pulmonary function tests, and provide a multi-component intervention at baseline. for suspected asthma population in the intervention arm, we provide community-based spirometry pulmonary function test (pft) and education; if individuals whose fev1 improved by ≥12% and ≥200 ml following bronchodilator administration with 400 ug salbutamol, they will be spirometry-defined undiagnosed asthma patient and will be encouraged to seek treatment and medication to the superior hospitals. additionally, we provide (1) two digital health intervention programs to smokers and individuals with mental health issues; (2) cbt-based health education for study participants with abnormal bmi; (3) active recruitment into national essential public health program in china for those with abnormal blood pressure and blood glucose. intensive follow-ups will be conducted at month 3 (telephone interview), month 6 (face-to-face with full steps of physical examination), and month 12. comparison: those who are assigned in the control arm, we will ask them to finish the same ecrhs online questionnaire with notification of his or her suspected asthma status and a face-to-face survey. no physical examinations, community-based pulmonary function tests will be given. outcomes: the primary outcomes are asthma knowledge, lung function testing, and act score at month 12.


Eligibility criteria:
inclusion criteria: * aged 35 and above; * score of ecrhs asthma screening questionnaire exceeds 0; * residents who have lived in one township over the past 3 months and plan to reside in the same township in the upcoming year; * finished the informed consent exclusion criteria: * pregnancy and other conditions that are not allowed to finish pulmonary function tests; * severe cognitive disorder or total loss of capability of daily living

Keywords: suspected asthma multimorbidity interventions and management clustered rct pay-for-population mechanism
effect of electrical stimulation (dc polarization) to the brain on memory

Conditions: Healthy

Summary: this study will test the effect of direct current (dc) brain polarization (the application of a very weak electrical current to the brain) on learning and memory. earlier studies have shown that dc polarization can temporarily improve the ability of healthy people to think of certain words. this study will explore whether it can also temporarily improve learning and memory. healthy people 18 years of age and older may be eligible for this study. subjects participate in two experimental sessions at the nih clinical center. the first session lasts about 1 hour; the second session, on the next day, takes about 10 minutes. at the beginning of the first session, electrodes are placed on the subject's head and arm for brain stimulation. the current may be turned on for 25 minutes, or only very briefly (sham stimulation). subjects are not told which type of stimulation they are receiving. no stimulation is applied in the second session. during the sessions subjects are asked to complete the following tasks that will help elucidate the effects of polarization: * read a list of words and remember them. later they will try to repeat the words from memory. * look at a series of designs and remember them. later they will try to draw the designs from memory. * push a button on a keyboard when they see a specific item (for example, when the number 7 appears). * generate as many words as they can think of that begin with a particular letter of the alphabet. subjects may be videotaped for some or all of the time during the sessions.

objective: the principal objective is to establish whether dc polarization of left lateral prefrontal cortex can enhance verbal memory. study population: 75 healthy volunteers over the age of 18 will be enrolled. design: the study is a double-blind parallel study with three arms: anodal polarization, cathodal polarization, and sham treatment. outcome measures: the primary outcome measure is performance on the wms-iii word lists test. secondary outcome measures, testing for effects of dc polarization on basic information processing and non-verbal memory, respectively, are the calcap and wms-iii visual reproduction test. the verbal fluency test will be administered prior to stimulation and 24 hours post-stimulation to screen for other residual effects of the polarization on the stimulated region.

Eligibility criteria:
* inclusion criteria: healthy volunteers over age 18. pregnancy is not an exclusion. exclusion criteria: any history of a central nervous system illness or other behavioral disorder. broken skin in the area of the electrodes. uncontrolled medical problems, such as diabetes mellitus, hypertension, airway disease, heart failure, coronary artery disease, or any other condition that poses a risk for the subject during participation. presence of metal in the cranial cavity. holes in the skull made by trauma or surgery.

Keywords: frontal lobe language dementia healthy volunteer hv
aggreguide 325 mg. aspirin study for aspirin induced platelet dysfunction

Conditions: Platelet Dysfunction Due to Aspirin Ingestion

Summary: to test the aggreguide a-100 aa assay's effectiveness for detecting aspirin induced platelet dysfunction.


Eligibility criteria:
inclusion criteria: * over 18 exclusion criteria: * on aspirin in prior week * medical history of platelet disorders * contraindications to aspirin
a study of apalutamide (adjuvant treatment) and androgen deprivation therapy (adt) in participants who have undergone radical prostatectomy (rp) for non-metastatic prostate cancer and who are at high risk for metastases

Conditions: Prostatic Neoplasms

Summary: main study: the purpose of main study is to assess if the combination of apalutamide and androgen deprivation therapy (adt) in participants with high-risk localized prostate cancer improves the biochemical recurrence (bcr) free rate. sub-study: the purpose of the sub-study is to assess if the co administration of apalutamide and relugolix is able to maintain castrate levels of testosterone.


Eligibility criteria:
inclusion criteria: * a candidate for radical prostatectomy (rp) or status post rp. eligible to receive study intervention between day 29 and day 90 post-rp. post rp prostate-specific antigen (psa) of \<= 0.2 nanograms per milliliter (ng/ml). has not received other treatment for prostate cancer * have recovered from rp procedure and have had no worsening in cardiac risk in the peri-operative period per the clinical judgement of the investigator * adequate organ function (hepatic, renal, hematologic and cerebral) determined at the discretion of the treating physician * eastern cooperative oncology group (ecog) performance status score of 0 or 1 * histologically confirmed adenocarcinoma of the prostate and categorized as high risk for recurrent prostate cancer. high risk can be defined based on psa alone or biopsy or rp specimen as follows: psa greater than or equal to (\>=) 20 ng/ml or; gleason score \>= 9 in any core on biopsy or; gleason score \>= 8 (4+4 or 5+3) in greater than (\>) 80 percentage (%) of 2 cores on biopsy or; gleason score = 8 (4+4 or 5+3) in 1 core as long 5 or more other cores with minimum gleason score of 4+3 on biopsy. the determination of high risk may be based on pathology report of biopsy or equivalent criteria from radical prostatectomy exclusion criteria: * history or presence of soft tissue/bone metastasis or metastasis in distant lymph nodes (pelvic lymph nodes below the iliac bifurcation that are less than (\<) 2 centimeter (cm) in diameter \[short axis\] either radiographically or pathologically are allowed.) * history of bilateral orchiectomy * received an investigational intervention \<= 4 weeks before the planned first dose of study intervention * history of seizure or any condition that in the opinion of the investigator may predispose to seizure or treatment with drugs known to lower the seizure threshold within 4 weeks prior to starting treatment with apalutamide * allergy or hypersensitivity to apalutamide, or excipients, unable or unwilling to take androgen deprivation therapy (adt)
a study to evaluate the effectiveness and safety of ozurdex® in patients with diabetic macular edema but never treated

Conditions: Diabetic Macular Edema

Summary: this study will evaluate the efficacy and safety of ozurdex in patients with diabetic macular edema when used in a real world setting in spain and portugal.


Eligibility criteria:
inclusion criteria: * prior diagnosis of diabetes mellitus (type 1 or type 2) * media clarity, pupillary dilation, and patient cooperation sufficient for all study procedures * written informed consent obtained in accordance with all local privacy requirements exclusion criteria: * uncontrolled systemic disease * history of disease, metabolic dysfunction, or clinical laboratory finding giving reasonable suspicion of a disease condition that contraindicates the use of the investigational drug, might affect the interpretation of study results, or render the patient at high risk from treatment complications * patients who have been previously treated for dme (two focal laser allowed) * untreated diabetes or anticipated change (increase) of antidiabetic medications during the study * elevated iop or glaucoma diagnosis * any active ocular infection or inflammation * aphakia * a substantial cataract is present that is likely to be decreasing visual acuity by three lines or more (i.e., cataract would be reducing visual acuity to 20/40 or worse if the eye was otherwise normal) * anticipated need for ocular surgery during the study * history of vitrectomy or incisional glaucoma surgery - female patients who are pregnant, nursing, or planning a pregnancy, or who are of childbearing potential and not using a reliable means of contraception * known allergy, hypersensitivity or contraindication to the study medication, its components, or povidone iodine
pld-cyclophosphamide-nab-p continuously combined with dual her2 blockage for her2-positive breast cancer

Conditions: Breast Cancer; HER2-positive Breast Cancer

Summary: patients with her2-positive breast cancer (ct2-3/n0-1/m0) were treated with pldchp (pegylated liposomal doxorubicin 35mg/m2, cyclophosphamide 600mg/m2, trastuzumab 8 mg/kg loading, then 6 mg/kg, pertuzumab 840 mg loading, then 420 mg, iv, q3w) for 4 cycles followed by nab-php (nab-paclitaxel 260mg/m2, trastuzumab 6 mg/kg, pertuzumab 420 mg, iv, q3w) for 4 cycles

upon approval by the medical ethics committee of xijing hospital, patients with her2-positive breast cancer (ct2-3/n0-1/m0) receiving neoadjuvant therapy, were enrolled. the patients were treated with pldchp (pegylated liposomal doxorubicin 35mg/m2, cyclophosphamide 600mg/m2, trastuzumab 8 mg/kg loading, then 6 mg/kg, pertuzumab 840 mg loading, then 420 mg, iv, q3w) for 4 cycles followed by nab-php (nab-paclitaxel 260mg/m2, trastuzumab 6 mg/kg, pertuzumab 420 mg, iv, q3w) for 4 cycles, with strict monitoring of cardiotoxicity. the primary endpoint was pcr rate, and secondary endpoints were cardiac safety during neoadjuvant therapy.

Eligibility criteria:
inclusion criteria: 1. her2-positive breast cancer 2. ct2-3/n0-1/m0 3. aged18-80 years 4. receiving neoadjuvant therapy 5. ecogps score 0 or 1 6. able to understand the test requirements, willing and able to comply with the test and follow-up procedures 7. adequate organ function exclusion criteria: 1. cardiac, hepatic, renal, or psychiatric disease history 2. history of other malignancy within the last 5 years, with the exception of adequately treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix.
an open label, single-arm clinical study evaluating the safety and efficacy of ici201 infusion in relapsed/refractory multiple myeloma

Conditions: Relapsed/Refractory Multiple Myeloma

Summary: an open label, single-arm clinical study evaluating the safety and efficacy of ici201 infusion in relapsed/refractory multiple myeloma


Eligibility criteria:
inclusion criteria: * 1. according to the multiple myeloma diagnostic criteria of the international myeloma working group (imwg), there is the initial diagnosis of multiple myeloma. 2. subjects must have previously received at least 3 anti-myeloma regimens. subjects must have documented disease progression (according to imwg criteria) during or within 12 months of completing their last anti-myeloma regimen prior to study entry; and prior regimens must have included proteasome inhibitor (pi) and immunomodulatory drug (imid). 3. measurable disease as defined by the protocol 4. ecog score is 0 or 1. 5. expected survival time ≥12 weeks. 6. gprc5d positive expression in bone marrow plasma cells exclusion criteria: * 1. patients suffering from graft-versus-host disease (gvhd) or requiring immunosuppressants drugs. 2. patients who received autologous hematopoietic stem cell transplantation (asct) or prior allogeneic hematopoietic stem cell transplantation (allo-hsct) within 12 weeks prior to mononuclear cell collection. 3. screening subjects who were receiving systemic steroids during the previous 7 days or who were determined by the investigator to require long-term systemic steroid use during treatment (except for inhaled or topical use, except at doses \< 10mg/ day). 4. patients with a history of hypertension that cannot be controlled by medication (blood pressure ≥140/90 mmhg). 5. patients who have recieved gprc5d-targeted therapy
weaning from mechanical ventilation in patients with acute brain injury

Conditions: Ventilator Lung; Acute Brain Injury

Summary: acute brain injury (abi) patients frequently necessate intubation and invasive mechanical ventilation (imv). while some abi patients are capable of breathing spontaneously, which is one of the main criteria of extubation and weaning. however, the rate of extubation failure was significantly higher in abi patients compared with non-neurological critical care patients. in patients who have failed one or several trials of extubation, tracheostomy is recommend according to the latest esicm consensus. tracheostomy can enhance comfort, improve pulmonary hygiene and decrease sedation requirement, which could facilitate the liberation from ventilator. numerous studies have explored the causes of weaning failure and provide various predictive models in guiding extubation and tracheostomy. yet, due to limitations of such as small sample size or a lack of external validation, there is paucity of practical weaning algorithm tailored for abi patients. the liberation from imv in abi patients still remains challenging with poor level of evidence in current guidelines or expert consensus. we aim to describe the weaning outcomes in abi patients, and further investigate the potential predictors of weaning success in abi patients.


Eligibility criteria:
inclusion criteria: * acute brain injury * age \>=18 years * invasive mechanical ventilation for at least 24 hours exclusion criteria: * tracheostomized before icu admission * pregnant or lactation * with cervical spinal cord injury * decision to receive palliative care within 24 hours of icu admission

Keywords: mechanical ventilation acute brain injury weaning
intra-tumor injection of drug-eluting microspheres with multiple drugs

Conditions: Hepatocellular Carcinoma; Solid Tumor, Adult

Summary: to study the safety and clinical effect of injection of drug-eluting microspheres with multiple chemodrug and/or protein drugs into advanced solid tumors.

drug-eluting microspheres such as dc-beads will be loaded with il2, pd1/pdl1/ctla4 antibody, or /and vegf/vegfr antibody with or without doxorubicin/idarubicin for various time and injected into tumors under ct guidance. side effects and treatment efficacy after injection of drug-eluting microspheres into malignant tumors will be assessed according to ricest1.1 standard.

Eligibility criteria:
inclusion criteria: * solid advanced malignant tumors * age between18 and 99 years * life expectancy is greater than three months exclusion criteria: * benign tumor * life expectancy is less than three months * serious medical comorbidity * others

Keywords: hepatocellular carcinoma; lung cancer; solid tumors drug-eluting beads il2; kytruda; opdivo; imfinza; atezolizumab; ipilimumab; treprizolizumab; tirelizumab; carellizumab; sintilimab; sugemalimab；adebrelimab；envafolimab；cadonilimab； bevacizumab; ramucirumab
iconographic registry of pancreatobiliary endoscopy procedures

Conditions: Pancreas Neoplasm; Cancer of Pancreas; Pancreatitis; Neuroendocrine Tumors

Summary: the aim of the tailor-eus study (iconographic registry of bilio-pancreatic endoscopic ultrasound procedures) is to establish a clinical registry comprising images and videos generated during endoscopic procedures conducted for the investigation of pancreatic diseases (pd). the study will compile historical, pathological, and imaging data from approximately 12,000 patients (2,000 retrospectively and 10,000 prospectively) who underwent endoscopic ultrasound procedures for inflammatory pancreatic conditions (e.g., acute, recurrent, chronic pancreatitis), autoimmune bilio-pancreatic diseases (e.g., autoimmune pancreatitis), neoplastic bilio-pancreatic conditions, and screenings for individuals at high risk of developing such diseases at the bilio-pancreatic endoscopy and endoscopic ultrasound unit of the irccs san raffaele hospital between 2000 and 2027. participants have undergone or will undergo the standard diagnostic pathway appropriate for their conditions as part of routine clinical practice. all instrumental examinations and endoscopic ultrasound procedures are integral to the standard diagnostic and therapeutic approach for pancreatic diseases.


Eligibility criteria:
inclusion criteria: * suspected or confirmed diagnosis of inflammatory pancreatic disease (e.g., acute, recurrent, or chronic pancreatitis) or autoimmune bilio-pancreatic disease (e.g., autoimmune pancreatitis) or bilio-pancreatic neoplastic disease, necessitating an endoscopic ultrasonography procedure. * age over 18 years. * ability to provide informed consent. exclusion criteria: * pregnancy and breastfeeding status. * contraindications to the endoscopic ultrasonography procedure
osteoporosis screening tools' re-validation in egypt guide for the management of the condition in males

Conditions: Osteoporosis

Summary: to demonstrate the predictive ability of the different screening scores (i.e. ost, orai, abone, body weight criterion, age alone or others) and their potential use in the primary care setting.

* a primary care sample of records at a local radiology center will be retrospectively reviewed and those of egyptian adults who underwent dxa scanning will be included. * those with prior diagnoses that can affect bone mineral density (bmd) (i.e. prior osteoporosis, paget's disease, osteomalacia, hyperparathyroidism, or hypogonadism) or history of using certain medications (i.e. bone-protective or anticonvulsant drugs) prior to undergoing the dxa scan will be excluded. * scores will be calculated as indicated in their respective studies after collecting the data pertaining to them (crandall, 2015); (cass \& shepherd, 2013); (reginster, et al., 2004); (adler, et al., 2003); (cadarette, et al., 2000); (weinstein \& ulery, 2000); (black, et al., 1998); (lydick, et al., 1998). * data will be treated as dichotomous for both dxa t-scores and screening scores (i.e. osteoporosis (yes or no) versus positive/negative score). a 2 x 2 contingency table will be constructed and the different diagnostic test statistics (i.e. sensitivities, specificities, receiver operating characteristic curve) will be calculated using different cut-off points to carry out sensitivity analyses (moreover, different dxa sites and cut-offs will be included in the analyses). spss version 25 software (ibm corp., usa) will be used for the statistical operations. * using an expected proportion of false negatives of 10% for sensitivity (i.e. based on the previous reported sensitivities for most tools being \>90% (crandall, 2015) and the performance of ost in egypt of 83% (el-masry, et al., 2015)) and a 95% confidence interval's width of 10% the needed sample size was estimated to be 138 (browner, et al., 2013, p. 81 table 6e). power analysis will be calculated for any deviation from this estimation. failure to meet sample size at the outset will be dealt with by prospectively screening new records for a period of 3 months. depending on the result, further recommendations and plans will be provided for possible applications and future research. all deviations from the protocol will be justified.

Eligibility criteria:
inclusion criteria: * adult patients undergoing dexa scan testing. exclusion criteria: * people with prior diagnoses that can affect bone mineral density (bmd) (i.e. prior osteoporosis, paget's disease, osteomalacia, hyperparathyroidism, or hypogonadism) or history of using certain medications (i.e. bone-protective or anticonvulsant drugs) prior to undergoing the dxa scan.

Keywords: osteoporosis
an observational study in participants with chronic hepatitis b (chb) receiving therapy with peginterferon alfa-2a 40 kilodaltons (kd) (pegasys) - the pro b study

Conditions: Hepatitis B, Chronic

Summary: this open--label, multicenter, national observational study will investigate the effectiveness of standard of care treatment with peginterferon alfa-2a in participants with chronic hepatitis b (chb). participants who have never received any hepatitis b virus (hbv) treatment and participants previously treated with nucleos(t)ide analogs (nas) are qualified for enrollment. the observation period is 48 weeks (peginterferon alfa--2a standard of care treatment) and for up to 24 weeks thereafter (72 weeks in total).


Eligibility criteria:
inclusion criteria: * hbeag positive or hbeag negative serologically proven chb with or without cirrhosis (histologically verified at some point in the past) * baseline hbv dna greater than (\>) 2000 iu/ml * elevated serum alt \> upper limit of normal (uln) * participants treated with previous nas therapy are eligible for this study exclusion criteria: * participants who have contraindications for peginterferon alfa-2a in accordance with the approved summary of product characteristics (for example, severe psychiatric diseases, immunological diseases, severe hepatic dysfunction or decompensated cirrhosis of the liver severe retinopathy or thyroid dysfunction, autoimmune hepatitis, history of severe pre-existing cardiac disease, or hypersensitivity to the active substance, to alpha interferons, or to any of the excipients) * participants with alt \> 10 times of uln or evidence of hepatocellular carcinoma * participants with serological evidence of co-infection with hepatitis a virus, hepatitis c virus, human immunodeficiency virus, or hepatitis d virus * participants with decompensated liver disease * pregnant or breast-feeding women * a history of liver transplantation or planned for liver transplantation